Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Apr 19;45(5):111.
doi: 10.1007/s00296-025-05862-y.

Effects of treatment with janus kinase inhibitors on coronary microvascular perfusion in patients with rheumatoid arthritis: an observational prospective cohort study

Panagiota Anyfanti  1 , Elena Angeloudi  2 , Eleni Pagkopoulou  3 , Maria Boutel  3 , Georgia-Savina Moysidou  4 , Kleopatra Deuteraiou  3 , Eleni Bekiari  2 , Michael Doumas  5 , George D Kitas  6   7 , Theodoros Dimitroulas  3
Affiliations
Observational Study

Effects of treatment with janus kinase inhibitors on coronary microvascular perfusion in patients with rheumatoid arthritis: an observational prospective cohort study

Panagiota Anyfanti et al. Rheumatol Int. .

Abstract

Despite their increasing use and their proven efficacy in the treatment of rheumatoid arthritis (RA), Janus kinase (JAK) inhibitors have been questioned by credible cardiovascular safety concerns. To date, mechanistic links of cardiovascular complications to JAK inhibitors remain largely unexplored. We aimed to investigate the effect of JAK inhibition on coronary microvascular blood flow in a previously published cohort of treated patients with RA. We prospectively enrolled RA patients initiating treatment with JAK inhibitors. Study procedures were performed at baseline and repeated 3 months after treatment. Patients underwent applanation tonometry in the radial artery to assess subendocardial viability ratio (SEVR) otherwise known as Buckberg index, a noninvasive marker of myocardial perfusion. Thirteen patients with RA were enrolled, of whom 11 completed the study. All patients presented with at least one cardiovascular risk factor (e.g., age ≥ 65 years, history of current or past smoking, obesity, hypertension). No change in other than antirheumatic treatment was performed during the study, and no significant changes were observed in baseline characteristics other than triglyceride levels. Compared to baseline, three months treatment with JAK inhibitors did not significantly alter SEVR values [126 (102-144) % vs. 134 (106-251) %, p = 0.083]. Three months treatment with JAK inhibitors did not seem to significantly affect myocardial perfusion in a small RA cohort with cardiovascular risk factors, who would be presumably more vulnerable to adverse treatment-related cardiovascular effects. Larger studies with longer follow-up are needed to document the effects of JAK inhibitors on the myocardium.

Keywords: Janus kinase inhibitors; Myocardial perfusion; Rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval and informed consent: The Institutional Review Board of Hippokration Hospital, Thessaloniki, Greece approved the study (protocol code 445/29-12-21, date of approval 17 February 2022). Participants gave informed consent to participate in the study before inclusion. The study was conducted in accordance with the principles of the Declaration of Helsinki. Disclosure: No part of this manuscript, including the text and graphics, are copied or published elsewhere in whole or in part. Conflict of interest: Panagiota Anyfanti, Elena Angeloudi, Eleni Pagkopoulou, Maria Boutel, Georgia-Savina Moysidou, Kleopatra Deuteraiou, Eleni Bekiari, Michael Doumas, and George D Kitas report no conflict of interest for this study. Theodoros Dimitroulas has received honoraria and advisory fees from Abbvie, Lilly, Pfizer and Sobi.

Figures

Fig. 1
Fig. 1
Change in SEVR from baseline to three-months treatment with JAK inhibitors in a prospectively studied sample of patients with RA
See this image and copyright information in PMC

References

    1. Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med 386:316–326. 10.1056/NEJMoa2109927 - PubMed
    1. Charles-Schoeman C, Buch MH, Dougados M et al (2023) Risk of major adverse cardiovascular events with Tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis 82:119–129. 10.1136/ard-2022-222259 - PMC - PubMed
    1. Smolen JS, Landewé RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3–18. 10.1136/ard-2022-223356 - PubMed
    1. European Medicines Agency (2022) EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. In: https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-...
    1. Fοοd and Drug Administration (2021) Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death. In: https://www.fda.gov/safety/medical-product-safety-information/janus-kina...

Publication types

LinkOut - more resources